

## Financial Tear Sheet

### Corporate Profile

XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide.

### Stock Information

XBIT (Common Stock)	
<b>Exchange</b>	NASDAQ (US Dollar)
<b>Price</b>	\$4.80
<b>Change (%)</b>	▲ 0.05 (1.05%)
<b>Volume</b>	72,570
<b>52 Week Low</b>	\$2.77
<b>Market Cap</b>	\$170,014,906
<b>Rolling EPS</b>	-1.47
<b>PE Ratio</b>	0
<b>Shares Outstanding</b>	35,419,772
Data as of 08/18/17 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

### Recent News

Date	Title
06/09/17	XBiotech Announces Discontinuation of Phase III Study for Colorectal Cancer Based on Second Interim Analysis
06/01/17	XBiotech Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer at the 2017 ASCO Meeting
05/30/17	Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Cancer

### Upcoming Events

There are currently no events scheduled.

## SEC Filings

Filing Date	Form
08/08/17	10-Q
07/11/17	4
07/11/17	3
06/26/17	4

## Management

John Simard	Founder, President, Chief Executive Officer & Chairman
Norma I. Gonzalez	Vice President of Quality
Benjamin Guzman	Senior Vice President of Corporate Strategy & Finance
Queena Han, C.P.A., C.G.A.	Vice President of Finance and Human Resources and Secretary
Sushma Shivaswamy, Ph.D.	Vice President of Research and Development
Michael Stecher, M.D.	Medical Director

## Primary IR Contact

James S. Whitehurst  
XBiotech  
**Phone:** +1 512.386.2993  
**Email:** swhitehurst@xbiotech.com

## Board of Directors

John Simard	Founder, President, Chief Executive Officer & Chairman
Fabrizio Bonanni, Dr. Chem.	Director
Thorpe McKenzie	Director
Daniel Vasella, M.D.	Director